Logo Image
News|Articles|August 28, 2024

Rapid Diagnostic Tests for Gastrointestinal Infectious Diseases

Author(s)Sophia Abene

MP Biomedicals’ tests detect Helicobacter pylori, Salmonella typhi, and Vibrio cholerae serogroups O1 and O139.

MP Biomedicals has introduced a new series of in vitro diagnostic tests that use immunochromatographic technology to detect gastrointestinal pathogens.The new kits focus on Helicobacter pylori, Salmonella typhi, and Vibrio cholerae serogroups O1 and O139. These diagnostic tools are designed to provide rapid and accurate results, enhancing the ability of healthcare professionals to detect and manage gastrointestinal infections.1

“We are excited to introduce these cutting-edge diagnostic kits, which represent a significant advancement in the field of gastrointestinal health,” according to MP Biomedical. “Our goal is to provide healthcare professionals with the tools they need to make accurate and timely diagnostics, ultimately improving patient care and outcomes. These kits reflect our commitment to innovation and excellence in the clinical diagnostics industry.”1

Key features of these diagnostic kits include CE-marking, suitability for professional in-vitro diagnostic use only, accuracy, rapid results, a one-step procedure, and no cross-reaction.1

Main Takeaways

  1. MP Biomedicals has introduced new rapid diagnostic tests for gastrointestinal pathogens, including Helicobacter pylori, Salmonella typhi, and Vibrio cholerae serogroups O1 and O139.
  1. The kits feature rapid, accurate results with a one-step procedure and are CE-marked for professional use, minimizing cross-reaction for reliable detection.
  1. These tests have public health implications by improving diagnosis and management of infections, potentially reducing gastric cancer risk, and aiding in the prevention of cholera outbreaks.

New Kits Overview

Rapid H pylori Antigen Test Card: An in-vitro qualitative assay for detecting H pylori antigens in human stool specimens. It aids in diagnosing H pylori infection, monitoring therapeutic effectiveness, and confirming eradication in peptic ulcer patients.1

According to research from Clinical Gastroenterology and Hepatology in April, H pylori is a major cause of gastric cancer (GC), particularly affecting racial and ethnic minorities who are also at higher risk for GC. Despite its classification as a Group 1 carcinogen and evidence showing that HP eradication lowers GC risk and mortality, routine screening is not currently practiced in the US. This targeted HP testing could potentially reduce GC incidence in high-risk populations.2

Rapid Salmonella typhi IgG/IgM Combo Test Card: This assay detects anti-S typhi antibodies in blood, plasma, or serum. It assists in diagnosing Salmonella typhi infections.

Typhoid and paratyphoid fevers, caused by Salmonella bacteria, are severe and life-threatening diseases often contracted during international travel to areas with poor sanitation. Routine testing can be limited in regions with fewer healthcare resources, so travelers or those at higher risk may need to seek specific medical advice or specialized services for testing.3

Rapid V cholerae O139 Test: Designed for the qualitative detection of Vibrio cholerae serogroup O139 in fecal samples, environmental water, or food. Also, the Rapid V cholerae O1 Test is like the O139 test but focuses on Vibrio cholerae serogroup O1. It is used for screening in fecal, water, or food specimens.1 By detecting these serogroups in water and food, these tests help prevent the spread of cholera in communities, safeguarding public health. With high mortality if untreated, accurate diagnosis enables timely treatment and containment, preventing outbreaks, especially in endemic regions or among travelers.4

These kits are available for order and reflect MP Biomedicals’ commitment to innovation in clinical diagnostics. Utilizing immunochromatographic technology, these tests are expected to improve diagnostic accuracy and efficiency in managing gastrointestinal infections.

References

  1. MP Biomedicals announces the launch of advanced gastrointestinal diseases diagnostic kits. NewsMedical. August 27, 2024. Accessed August 28, 2024. https://www.news-medical.net/news/20240827/MP-Biomedicals-announces-the-launch-of-advanced-gastrointestinal-diseases-diagnostic-kits.aspx
  2. Shria Kumar et al, Barriers to Community-Based Eradication of Helicobacter pylori Infection, Clinical Gastroenterology and Hepatology (2024). April 3, 2024. Accessed August 28, 2024. DOI: 10.1016/j.cgh.2024.03.008
  3. About Typhoid Fever and Paratyphoid Fever. CDC. April 25, 2024. Accessed August 28, 2024. https://www.cdc.gov/typhoid-fever/about/index.html
  4. Pindyck T, Gutelius B, Mintz E. Cholera. CDC Yellow Book 2024. Accessed August 28, 2024. https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/cholera#:~:text=In%20the%20United%20States%2C%20cholera,patient%20with%20acute%2C%20watery%20diarrhea.

Related to this article

View more
IDSA/ESCMID Statement on Staphylococcus aureus: Follow-Up Blood Cultures
IDSA/ESCMID Statement on Staphylococcus aureus: Follow-Up Blood Cultures
Staphylococcus aureus Bacteremia (SAB) causes significant morbidity and globally is the leading cause of death from bloodstream infection. This month, the IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.
Read more
Measles Update: September 25, 2026
Measles Update: September 25, 2026
The latest CDC numbers show a 5.4% increase of measles cases from week-to-week. This year has already become the worst for the number of measles cases in the US since the disease was declared eliminated in 2000. With the start of respiratory virus season, case numbers are expected to continue to increase significantly.
Read more